Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ProKidney (PROK)
NASDAQ:PROK
Holding PROK?
Track your performance easily
PROK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.12 - $4.44
Previous Close$1.62
Volume926.48K
Average Volume (3M)655.13K
Market Cap
$451.89M
Enterprise Value$1.47B
Total Cash (Recent Filing)$431.53M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Nov 12, 2024EPS Estimate
-$0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding289,675,217
10 Day Avg. Volume339,611
30 Day Avg. Volume655,128
Standard Deviation0.23
R-Squared0.08
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-0.55
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-11.34
Forecast
1Y Price Target
$4.25Price Target Upside132.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
ProKidney News
PremiumCompany Announcements
ProKidney: Investor Update and Phase 3 Program Progress
Bulls Say, Bears Say
Bulls Say
Market PotentialRilparencel is a differentiated approach in diabetic CKD with blockbuster potential.
Regulatory PathwayProKidney continues to engage with FDA under its RMAT designation, which entails review process benefits similar to breakthrough therapy designation.
Strategic DecisionsThe decision to discontinue PROACT 2 is expected to result in savings of $150M to $175M, extending the company's cash runway.
Bears Say
Data ReliabilityThe sample size of the most recent data from the REGEN-007 study is small.
Financial ConcernsThe company’s cash runway stops ~half a year short of the pivotal readout for the company’s cell therapy treatment aimed at delaying or stopping progression of chronic kidney disease.
Operational ChallengesThe extension of cash runway falls short of the Ph3 study completion, which PROK expects to be completed in 3Q27.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PROK FAQ
What was ProKidney’s price range in the past 12 months?
ProKidney lowest stock price was $1.12 and its highest was $4.44 in the past 12 months.
What is ProKidney’s market cap?
Currently, no data Available
When is ProKidney’s upcoming earnings report date?
ProKidney’s upcoming earnings report date is Nov 12, 2024 which is in 2 days.
How were ProKidney’s earnings last quarter?
ProKidney released its earnings results on Aug 09, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.253 by $0.093.
Is ProKidney overvalued?
According to Wall Street analysts ProKidney’s price is currently Undervalued.
Does ProKidney pay dividends?
ProKidney does not currently pay dividends.
What is ProKidney’s EPS estimate?
ProKidney’s EPS estimate is -$0.13.
How many shares outstanding does ProKidney have?
ProKidney has 126,051,384 shares outstanding.
What happened to ProKidney’s price movement after its last earnings report?
ProKidney reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.253. Following the earnings report the stock price went up 4.306%.
Which hedge fund is a major shareholder of ProKidney?
Among the largest hedge funds holding ProKidney’s share is Wexford Capital LP. It holds ProKidney’s shares valued at N/A.
---
ProKidney Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.25 (132.24% Upside)
$4.25 (132.24% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 12.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.09%
Trailing 12-Months
Company Description
ProKidney
Social Capital Suvretta Holdings Corp III is a blank check company.
---
PROK Company Deck
---
PROK Earnings Call
Q3 2023
0:00 / 0:00
---
PROK Stock 12 Month Forecast
Average Price Target
$4.25
▲(132.24% Upside)
Technical Analysis
Best Analysts Covering PROK
1 Year
1 Year Success Rate
1/9 ratings generated profit
1 Year Average Return
-41.54%
reiterated a buy rating 2 months ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -41.54% per trade.
---